Richard Cashin, Jr. Buys 447,100 Shares of AdaptHealth (NASDAQ:AHCO) Stock

AdaptHealth Corp. (NASDAQ:AHCO) major shareholder Richard Cashin, Jr. bought 447,100 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The shares were acquired at an average cost of $9.91 per share, with a total value of $4,430,761.00. Following the purchase, the insider directly owned 16,312,698 shares of the company’s stock, valued at $161,658,837.18. This trade represents a 2.82% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

AdaptHealth Price Performance

Shares of AHCO opened at $11.48 on Wednesday. AdaptHealth Corp. has a 52-week low of $7.11 and a 52-week high of $11.69. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.81 and a current ratio of 1.02. The business’s 50 day moving average price is $10.11 and its two-hundred day moving average price is $9.74. The firm has a market cap of $1.56 billion, a PE ratio of -20.87, a price-to-earnings-growth ratio of 1.19 and a beta of 1.76.

AdaptHealth (NASDAQ:AHCO) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.76) EPS for the quarter, missing the consensus estimate of $0.34 by ($1.10). The company had revenue of $846.29 million for the quarter, compared to analyst estimates of $832.51 million. AdaptHealth had a positive return on equity of 3.42% and a negative net margin of 2.18%.The business’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same period last year, the business earned $0.34 EPS. On average, equities analysts anticipate that AdaptHealth Corp. will post 0.88 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Rockefeller Capital Management L.P. lifted its stake in shares of AdaptHealth by 433.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 2,585 shares of the company’s stock valued at $26,000 after buying an additional 2,100 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in shares of AdaptHealth during the third quarter worth about $35,000. PNC Financial Services Group Inc. increased its position in shares of AdaptHealth by 22.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,003 shares of the company’s stock worth $70,000 after acquiring an additional 1,279 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of AdaptHealth by 318.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,592 shares of the company’s stock worth $90,000 after acquiring an additional 7,297 shares during the last quarter. Finally, Tidal Investments LLC acquired a new stake in shares of AdaptHealth in the 2nd quarter worth about $96,000. Institutional investors and hedge funds own 82.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Wall Street Zen downgraded shares of AdaptHealth from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Royal Bank Of Canada reissued an “outperform” rating and set a $13.00 price objective on shares of AdaptHealth in a research report on Wednesday, February 25th. Zacks Research raised AdaptHealth from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 1st. Leerink Partners dropped their price target on AdaptHealth from $13.00 to $12.00 and set an “outperform” rating on the stock in a research note on Thursday, February 26th. Finally, Weiss Ratings lowered AdaptHealth from a “hold (c-)” rating to a “sell (d)” rating in a report on Wednesday, February 25th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $13.25.

More AdaptHealth News

Here are the key news stories impacting AdaptHealth this week:

• Positive Sentiment: Major insider buy — Richard M. Cashin, Jr. purchased 447,100 shares at an average price of $9.91 on March 20, increasing his stake to ~16.31M shares (a ~2.8% increase). Large insider purchases are typically viewed as a vote of confidence by a controlling shareholder. Insider Buying: AdaptHealth Major Shareholder Purchases 447,100 Shares Adapthealth corp: Richard Cashin buys $4.4m in AHCO stock
• Neutral Sentiment: Analyst and institutional backdrop — mixed analyst moves (RBC and Leerink on the bullish side, Wall Street Zen/Weiss more cautious) but MarketBeat consensus remained around a “Moderate Buy” with a ~$13.25 target; long-term institutional ownership is high (~82.7%), which can limit free float and amplify moves.
• Negative Sentiment: Elevated and inconsistent short-interest prints — one report shows short interest rose to ~9.04M shares as of March 13 (up 22.5% from Feb. 26), representing ~6.8% shorted and a ~5.1 days-to-cover figure — a meaningful short position that can pressure the stock and raise volatility. However, multiple subsequent data entries show 0 shares/NaN (clearly erroneous), so short-interest figures are currently inconsistent across data vendors; the mixed prints themselves can generate trading noise and confusion for investors.

About AdaptHealth

AdaptHealth, Inc operates as a leading provider of home medical equipment (HME) and related services in the United States. The company focuses on delivering respiratory care, mobility solutions and bathroom safety products to patients with chronic and acute medical needs. Through its comprehensive service offerings, AdaptHealth aims to enhance quality of life and clinical outcomes for patients who require long-term support outside of a hospital setting.

The company’s respiratory portfolio includes products such as continuous positive airway pressure (CPAP) devices, oxygen concentrators, ventilators, and associated supplies for patients with sleep apnea, COPD and other pulmonary conditions.